Latest Health News

Monash IVF Group has appointed Dr Victoria Atkinson as its new Managing Director and CEO, effective May 2026, signaling a strategic leadership shift for the assisted reproductive services provider.

Scentre Group reports rising customer visits and strong sales growth across its Westfield portfolio, while confirming its 2025 earnings and distribution targets.

Scentre Group reports a 3.1% rise in customer visits and a $29.5 billion sales tally across its Westfield centres, while confirming its 2025 earnings and distribution targets.

Scentre Group reports a solid operating update for 2025, highlighting increased customer visits, rising business partner sales, and near-full occupancy across its Westfield centres.

NeuroScientific Biopharmaceuticals has initiated treatment of its fourth patient under the Special Access Scheme for StemSmart™, progressing towards a Phase 2 trial targeting severe Crohn’s disease.

Etherstack plc reports a record-breaking FY25 with revenues up 62%, driven by major US and UK contracts, and projects continued strong growth into FY26 and beyond.

Bendigo and Adelaide Bank’s latest Basel III disclosures reveal a slight dip in capital ratios offset by improved liquidity and funding stability for the quarter ended September 2025.

Invex Therapeutics has appointed two new non-executive directors and joint company secretaries, signaling a refreshed governance structure alongside a change of company address.

NRW Holdings showcased strong FY25 proforma results and ambitious FY26 guidance at the UBS Conference, underpinned by strategic acquisitions and a diversified portfolio. The company’s growth strategy focuses on expanding capabilities in energy transition and infrastructure markets across Australia, New Zealand, and North America.

The a2 Milk Company is expanding its strategic partnership with China State Farm to include English label infant milk formula products, starting with a2 Genesis™ in early 2026. This move aims to strengthen distribution control and capitalize on China’s booming infant formula market.

Regal Asian Investments Limited has announced an on-market buy-back of its ordinary shares, set to run from November 2025 through November 2026, signaling a strategic move to manage its capital structure.

Mayne Pharma’s acquisition by Cosette Pharmaceuticals faces a regulatory delay as the Foreign Investment Review Board extends its approval deadline, pushing the court hearing to mid-November.